PARP Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Posted on
by

PARP Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “PARP inhibitor Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PARP inhibitor therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive PARP inhibitor Pipeline Report @ PARP inhibitor Pipeline Outlook Report

Key Takeaways from the PARP inhibitor Pipeline Report

  • On March 25, 2026- Dana-Farber Cancer Institute conducted a study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. The FDA (the U.S. Food and Drug Administration) has not approved niraparib for this specific disease but it has been approved for other uses.
  • On March 11, 2026- Pfizer initiated a study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
  • On March 10, 2026- Tesaro Inc. announced a phase 3 study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
  • On March 02, 2026- AstraZeneca conducted a phase I/II study is a Phase I/IIa modular, open-label, multi-center study of AZD5335 administered either as monotherapy or in combination with other anti-cancer agents in participants with advanced solid malignancies
  • DelveInsight’s PARP inhibitor pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PARP inhibitor treatment.
  • The leading PARP inhibitor Companies such as TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others
  • Promising PARP inhibitor Therapies such as Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin and others.

Access DelveInsight’s in-depth PARP inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ PARP inhibitor Clinical Trials and Studies

The PARP Inhibitor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The PARP Inhibitor Pipeline Report also highlights the unmet needs with respect to the PARP Inhibitor.

PARP Inhibitor Overview

PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1. This enzyme was first reported in 1963. In 1980 Durkacz et al. proposed that modulating PARP1 might augment the effect of alkylator chemotherapy.

PARP inhibitor Emerging Drugs Profile

  • Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Get a detailed analysis of the latest innovations in the PARP inhibitor pipeline. Explore DelveInsight’s expert-driven report today! @ PARP inhibitor Unmet Needs

The PARP inhibitor Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of PARP inhibitor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PARP inhibitor Treatment.
  • PARP inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • PARP inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PARP inhibitor market.

PARP inhibitor Companies

TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others.

PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type

PARP inhibitor Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Download DelveInsight’s latest report to gain strategic insights into upcoming PARP inhibitor Therapies and key Developments @ PARP inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the PARP inhibitor Pipeline Report

  • Coverage- Global
  • PARP inhibitor Companies- TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others
  • PARP inhibitor Therapies- Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin and others.
  • PARP inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • PARP inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive PARP inhibitor Pipeline Report—access it now! @ PARP inhibitor Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. PARP Inhibitors: Overview
  4. Structure
  5. Mechanism of Action
  6. Pipeline Therapeutics
  7. Comparative Analysis
  8. Therapeutic Assessment
  9. Assessment by Product Type
  10. Assessment by Stage and Product Type
  11. Assessment by Route of Administration
  12. Assessment by Stage and Route of Administration
  13. Assessment by Molecule Type
  14. Assessment by Stage and Molecule Type
  15. PARP Inhibitors – DelveInsight’s Analytical Perspective
  16. In-depth Commercial Assessment
  17. PARP Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  18. PARP Inhibitors Collaboration Deals
  19. Company-Company Collaborations (Licensing / Partnering) Analysis
  20. Company-University Collaborations (Licensing / Partnering) Analysis
  21. Late Stage Products (Phase III)
  22. Comparative Analysis
  23. Pamiparib: BeiGene
  24. Product Description
  25. Research and Development
  26. Product Development Activities
  27. Drug profiles in the detailed report…..
  28. Mid Stage Products (Phase II)
  29. Comparative Analysis
  30. Drug Name: Company Name
  31. Product Description
  32. Research and Development
  33. Product Development Activities
  34. Drug profiles in the detailed report…..
  35. Pre-clinical and Discovery Stage Products
  36. Comparative Analysis
  37. Drug Name: Company Name
  38. Product Description
  39. Research and Development
  40. Product Development Activities
  41. Drug profiles in the detailed report…..
  42. Inactive Products
  43. Comparative Analysis
  44. PARP Inhibitors Key Companies
  45. PARP Inhibitors Key Products
  46. PARP Inhibitors- Unmet Needs
  47. PARP Inhibitors- Market Drivers and Barriers
  48. PARP Inhibitors- Future Perspectives and Conclusion
  49. PARP Inhibitors Analyst Views
  50. PARP Inhibitors Key Companies
  51. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight